Exciting news for SteriPlas activity in Taiwan
Exciting Success for SteriPlas Cold Plasma in Taiwan!
We are proud to share incredible news from our trusted medical distributor, SG Biomedical, who have successfully introduced our SteriPlas Premium Cold Plasma medical device to six leading hospitals across Taiwan. Over 100 patients have been treated in 2024 with remarkable outcomes.
These patients presented with complex wound infections, including:
🩺 Diabetic foot ulcers
🩺 Pressure ulcers
🩺 Chronic burns
🩺 Skin graft donor site complications
🩺 Autoimmune disease-associated wounds
🩺 LVAD infections
🩺 Cellulitis
🩺 Post-surgical wounds
Ranging from ages 29 to 104, all patients had previously suffered from stalled healing due to chronic biofilm complications. After treatment with the SteriPlas, patients have experienced positive healing outcomes, with many achieving full recovery and others showing ongoing progress toward healing. Importantly, no side effects have been observed during treatments.
This breakthrough highlights the transformative impact of the SteriPlas on chronic infections where other treatments have failed. We're immensely grateful to SG Biomedical and the healthcare professionals who continue to deliver life-changing care to patients in Taiwan.
Together, we’re redefining possibilities in wound care.
